12th Annual General Meeting of the BioLawEurope organisation in Prague, Czech Republic on 21 - 23 May 2026
We ♥️ Life Sciences – BioLawEurope AGM 2026 in Prague
Insightful discussions, fresh perspectives and inspiring exchanges at this year’s BioLawEurope Annual General Meeting in beautiful Prague once again demonstrated the importance of cross-border dialogue💡
Our professional program focused on some key regulatory and market developments in the life sciences and healthcare sector across Europe (plus interesting insights from our US member Brian Hand), including:
the evolving role of pharmacies within primary care delivery models – presented by Igor Pieš
a comparative survey on university spin-outs, focusing on IP allocation mechanisms, legal frameworks and equity participation models practices across the BLE members' jurisdictions – presented by Jan Bjerrum Bach based on contributions from BioLawEurope members
clinical trial data and the evolving impact of the European Health Data Space (EHDS) and the EU Digital Omnibus initiative – presented by Agnieszka Wozniak
We likewise had an engaging exchange on the potential implications of the US “Most Favored Nation” pharmaceutical pricing policy for drug pricing and availability across Europe – and many further discussions.
A heartfelt thank you to our wonderful hosts Igor Pieš and Eliška Toušková for the warm welcome, outstanding organization and making us experience true Prague hospitality. 🇨🇿
And a sincere thank you to all BioLawEurope members and participants for the lively talks, valuable insights and continued collaboration across the BioLawEurope network. Looking forward to meet up again – latest next year in beautiful Stockholm! 🇸🇪




Comments